Latest NmVac4-A/C/Y/W-135 Stories
A study of 4CMenB, a new vaccine to protect against meningitis B bacteria (which can cause potentially fatal bacterial meningitis in children), shows that waning immunity induced by infant vaccination can be overcome by a booster dose at 40 months of age.
Evaluation of the effectiveness of a mass vaccination campaign with a new meningitis serogroup A vaccine, PsA-TT, in sub-Saharan Africa found that it had a dramatic impact on cases of serogroup meningitis and on carriage of the disease-causing bacteria in the throat.
This study is a Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial to Assess the Safety, Tolerability and Immunogenicity of a new Meningococcal Vaccine When Given in Healthy Subjects
- To give a box on the ear to.